Cargando…

A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution

PURPOSE: A lipid-based, nanomicelle-loaded docetaxel (M-DOC) was designed and characterized. Optical imaging was employed to evaluate the pharmacokinetics and antitumor efficacy of docetaxel in vivo. MATERIALS AND METHODS: The M-DOC was prepared using the emulsion-diffusion method. Transmission elec...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Mingshu, Hao, Yanli, Liu, Nan, Yin, Zhe, Wang, Lan, Liang, Xingjie, Zhang, Xiaoning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405881/
https://www.ncbi.nlm.nih.gov/pubmed/22848167
http://dx.doi.org/10.2147/IJN.S29827
_version_ 1782239172221730816
author Ma, Mingshu
Hao, Yanli
Liu, Nan
Yin, Zhe
Wang, Lan
Liang, Xingjie
Zhang, Xiaoning
author_facet Ma, Mingshu
Hao, Yanli
Liu, Nan
Yin, Zhe
Wang, Lan
Liang, Xingjie
Zhang, Xiaoning
author_sort Ma, Mingshu
collection PubMed
description PURPOSE: A lipid-based, nanomicelle-loaded docetaxel (M-DOC) was designed and characterized. Optical imaging was employed to evaluate the pharmacokinetics and antitumor efficacy of docetaxel in vivo. MATERIALS AND METHODS: The M-DOC was prepared using the emulsion-diffusion method. Transmission electron microscopy and dynamic light scattering were used to assess the morphology and particle size of the M-DOC. Critical micelle concentrations, their stability under physiological conditions, and their encapsulation efficiency – as measured by high-performance liquid chromatography – were assessed. Pharmacological features were evaluated in two different animal models by comparing M-DOC treatments with docetaxel injections (I-DOC). Bioluminescence imaging was used to assess antitumor activity and docetaxel distribution in vivo, using nude mice injected with luciferase-expressing MDA-MB-231 human breast tumor cells. In addition, animals injected with B16 melanoma cells were used to measure survival time and docetaxel distribution. RESULTS: The M-DOC was prepared as round, uniform spheres with an effective diameter of 20.8 nm. The critical micelle concentration of the original emulsion was 0.06%. Satisfactory encapsulation efficiency (87.6% ± 3.0%) and 12-hour stability were achieved. Xenograft results demonstrated that the M-DOC was more effective in inhibiting tumor growth, without significantly changing body weight. Survival was prolonged by 12.6% in the M-DOC group. Tumor growth inhibitory rates in the M-DOC and I-DOC groups were 91.2% and 57.8% in volume and 71.8% and 44.9% in weight, respectively. Optical bioluminescence imaging of tumor growths yielded similar results. Area under the curve((0–6 hour)) levels of docetaxel in blood and tumors were significantly higher in the M-DOC group (15.9 ± 3.2 μg/mL(−1), 601.1 ± 194.5 μg/g(−1)) than in the I-DOC group (7.2 ± 1.7 μg/mL(−1), 357.8 ± 86.2 μg/g(−1)). The fluorescent dye 1,1-dioctadecyl-3,3,3,3′-tetramethylindotricarbocyanine iodide mimicked M-DOC in optical imaging, and accumulated more in tumors in comparison with I-DOC. CONCLUSION: These results suggest that the lipid-based nanomicelle system was effective in inhibiting tumor growth, with little toxicity. Moreover, we have developed a noninvasive optical imaging method for antitumor drug evaluation, which merits further analysis for potential clinical applications.
format Online
Article
Text
id pubmed-3405881
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-34058812012-07-30 A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution Ma, Mingshu Hao, Yanli Liu, Nan Yin, Zhe Wang, Lan Liang, Xingjie Zhang, Xiaoning Int J Nanomedicine Original Research PURPOSE: A lipid-based, nanomicelle-loaded docetaxel (M-DOC) was designed and characterized. Optical imaging was employed to evaluate the pharmacokinetics and antitumor efficacy of docetaxel in vivo. MATERIALS AND METHODS: The M-DOC was prepared using the emulsion-diffusion method. Transmission electron microscopy and dynamic light scattering were used to assess the morphology and particle size of the M-DOC. Critical micelle concentrations, their stability under physiological conditions, and their encapsulation efficiency – as measured by high-performance liquid chromatography – were assessed. Pharmacological features were evaluated in two different animal models by comparing M-DOC treatments with docetaxel injections (I-DOC). Bioluminescence imaging was used to assess antitumor activity and docetaxel distribution in vivo, using nude mice injected with luciferase-expressing MDA-MB-231 human breast tumor cells. In addition, animals injected with B16 melanoma cells were used to measure survival time and docetaxel distribution. RESULTS: The M-DOC was prepared as round, uniform spheres with an effective diameter of 20.8 nm. The critical micelle concentration of the original emulsion was 0.06%. Satisfactory encapsulation efficiency (87.6% ± 3.0%) and 12-hour stability were achieved. Xenograft results demonstrated that the M-DOC was more effective in inhibiting tumor growth, without significantly changing body weight. Survival was prolonged by 12.6% in the M-DOC group. Tumor growth inhibitory rates in the M-DOC and I-DOC groups were 91.2% and 57.8% in volume and 71.8% and 44.9% in weight, respectively. Optical bioluminescence imaging of tumor growths yielded similar results. Area under the curve((0–6 hour)) levels of docetaxel in blood and tumors were significantly higher in the M-DOC group (15.9 ± 3.2 μg/mL(−1), 601.1 ± 194.5 μg/g(−1)) than in the I-DOC group (7.2 ± 1.7 μg/mL(−1), 357.8 ± 86.2 μg/g(−1)). The fluorescent dye 1,1-dioctadecyl-3,3,3,3′-tetramethylindotricarbocyanine iodide mimicked M-DOC in optical imaging, and accumulated more in tumors in comparison with I-DOC. CONCLUSION: These results suggest that the lipid-based nanomicelle system was effective in inhibiting tumor growth, with little toxicity. Moreover, we have developed a noninvasive optical imaging method for antitumor drug evaluation, which merits further analysis for potential clinical applications. Dove Medical Press 2012 2012-07-04 /pmc/articles/PMC3405881/ /pubmed/22848167 http://dx.doi.org/10.2147/IJN.S29827 Text en © 2012 Ma et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Ma, Mingshu
Hao, Yanli
Liu, Nan
Yin, Zhe
Wang, Lan
Liang, Xingjie
Zhang, Xiaoning
A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title_full A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title_fullStr A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title_full_unstemmed A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title_short A novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
title_sort novel lipid-based nanomicelle of docetaxel: evaluation of antitumor activity and biodistribution
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405881/
https://www.ncbi.nlm.nih.gov/pubmed/22848167
http://dx.doi.org/10.2147/IJN.S29827
work_keys_str_mv AT mamingshu anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT haoyanli anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT liunan anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT yinzhe anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT wanglan anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT liangxingjie anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT zhangxiaoning anovellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT mamingshu novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT haoyanli novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT liunan novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT yinzhe novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT wanglan novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT liangxingjie novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution
AT zhangxiaoning novellipidbasednanomicelleofdocetaxelevaluationofantitumoractivityandbiodistribution